← ireadpaper · 顶刊中的公共政策研究

费用分担的健康成本

The Health Costs of Cost Sharing
Quarterly Journal of Economics · 2024 · [{"name": "Amitabh Chandra", "affiliation": ["National Bureau of Economic Research"]}, {"name": "Evan Flack", "affiliation": ["Stanford University"]}, {"name": "Ziad Obermeyer", "affiliation": ["National Bureau of Economic Research", "University of California, Berkeley"]}]

中文摘要

当患者突然停药时会发生什么?我们研究了由价格大幅、突然且任意变化所导致的药物中断的健康后果。Medicare 处方药福利根据 65 岁人群的出生月份近乎随机地为其分配一个药品预算,超过该预算后自付费用会骤然上升。面临较小预算的人群用药更少、死亡更多:预算每月减少 100 美元(24.4%),死亡率每月上升 0.0164 个百分点(13.9%)。这一估计结果对一系列证伪检验保持稳健,并位于 544 个来自缺乏同类特异性预算政策的相似人群的安慰剂估计值中的第 97.8 百分位。若干事实有助于理解这一巨大效应。第一,患者停用的药物往往兼具高价值,且被怀疑在停药时会引发危及生命的戒断综合征。第二,我们利用机器学习识别出药物可预防不良事件风险最高的患者。与标准经济模型的预测相反,高风险患者(例如最可能发生心脏病发作者)恰恰在对其获益最大的药物(如他汀类药物)上,比低风险患者削减得更多。最后,患者似乎并未意识到这些风险:在一项针对 65 岁人群的调查中,只有三分之一的人认为停药长达一个月可能带来任何严重后果。我们得出结论:费用分担远非遏制浪费,其本身高度低效,导致本可以极低成本(每生命年 11,321 美元)购买健康的机会被错失。

Abstract

What happens when patients suddenly stop their medications? We study the health consequences of drug interruptions caused by large, abrupt, and arbitrary changes in price. Medicare's prescription drug benefit as-if-randomly assigns 65-year-olds a drug budget as a function of their birth month, beyond which out-of-pocket costs suddenly increase. Those facing smaller budgets consume fewer drugs and die more: mortality increases 0.0164 percentage points per month (13.9%) for each $100 per month budget decrease (24.4%). This estimate is robust to a range of falsification checks and lies in the 97.8th percentile of 544 placebo estimates from similar populations that lack the same idiosyncratic budget policy. Several facts help make sense of this large effect. First, patients stop taking drugs that are both high value and suspected to cause life-threatening withdrawal syndromes when stopped. Second, using machine learning, we identify patients at the highest risk of drug-preventable adverse events. Contrary to the predictions of standard economic models, high-risk patients (e.g., those most likely to have a heart attack) cut back more than low-risk patients on exactly those drugs that would benefit them the most (e.g., statins). Finally, patients appear unaware of these risks. In a survey of 65-year-olds, only one-third believe that stopping their drugs for up to a month could have any serious consequences. We conclude that far from curbing waste, cost sharing is itself highly inefficient, resulting in missed opportunities to buy health at very low cost ($11,321 per life-year).
在 ireadpaper 查看全部 →